Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 655-661

  Romero, A ^a   Garcia Saenz J A ^a   Fuentes Ferrer, M ^a   Lopez Garcia Asenjo J A ^b   Furio V ^c   Roman J M ^a   Moreno, A ^a   De la Hoya, M ^a   Diaz Rubio E ^a   Martin M ^d   Caldes T ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c Department of Pathology ^*  (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Breast cancer; Neoadjuvant chemotherapy response.

Indexed keywords

DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; LOCALLY ADVANCED CANCER; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84874562623     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds493     Document Type: Article

References (28)

1. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994; 74(1 Suppl): 416-23.
2. Bonadonna G, Veronesi U, Brambilla C et al.. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-45.
3. Bonadonna G, Valagussa P, Brambilla C et al.. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
4. Honkoop AH, Pinedo HM, De Jong JS et al.. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997; 107: 211-218.
5. Fisher B, Bryant J, Wolmark N et al.. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
6. Kaufmann M, Hortobagyi GN, Goldhirsch A et al.. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-1949.
7. Eisenhauer EA, Therasse P, Bogaerts J et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
8. Therasse P, Arbuck SG, Eisenhauer EA et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
9. Ogston KN, Miller ID, Payne S et al.. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12: 320-327.
10. Symmans WF, Peintinger F, Hatzis C et al.. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422.
11. Martin M, Romero A, Cheang MC et al.. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011; 128: 127-136.
12. Romero A, Martín M, Cheang MC et al.. Assessment of Topoisomerase II a status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Assessment of topoisomerase II a status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 2011; 178: 1453-1460.
13. Romero A, Martín M, Oliva B et al.. Glutathione S Transferase P1 c.313A>G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol 2012; 23: 1750-1756.
14. Guarneri V, Broglio K, Kau SW et al.. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
15. Hennessy BT, Hortobagy GN, Rouzier RN et al.. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-9311.
16. Kuerer HM, Newman LA, Smith TL et al.. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
17. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004; 11: 139-47.
18. Gounaris I, Provenzano E, Vallier AL et al.. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2011; 127: 459-69.
19. von Minckwitz G, Kímmel S, Vogel P et al.. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomised GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562.
20. Chagpar AB, Middleton LP, Sahin AA et al.. Accuracy of physical examination, mammography and ultrasonography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006; 243: 257-264.
21. Yeh E, Slanetz P, Kopans DB et al.. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005; 184: 868-877.
22. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69: 2849-2852.
23. Kim HJ, Im YH, Han BK et al.. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol 2007; 46: 996-1003.
24. Bear HD, Anderson S, Smith RE et al.. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B- 27. J Clin Oncol 2006; 24: 2019-27.
25. Carey LA, Metzger R, Dees EC et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137-42.
26. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from the National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
27. Chollet P, Amat S, Cure H et al.. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-1046.
28. Montagna E, Bagnardi V, Rotmensz N et al.. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010; 124: 689-99.